VIDEO: Interchangeability and Rheumatology Prescribing Practices
by Ha Kung Wong
October 31, 2017
Watch Ha Kung Wong, Angus Worthing, Amanda Forys, and Molly Burich discuss questions regarding physician prescribing of biosimilars and interchangeables, including how the designation of a product as interchangeable will affect prescribing practices and how interchangeability designations will affect the uptake of biosimilars and interchangeables in the market, as part of the The Center for Biosimilars™ Peer Exchange®.
Ha Kung Wong
has extensive experience litigating a wide variety of pharmaceutical cases, including those concerning biologics used to treat rheumatoid arthritis and autoimmune disorders. He also has extensive experience consulting, conducting due diligence and licensing pharmaceutical portfolios. Ha Kung has a B.S. in Biochemistry and a B.S. in Chemistry.